Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Free Report) Director Rosty Raykov sold 2,431 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $4.94, for a total value of $12,009.14. Following the completion of the sale, the director now directly owns 66,432 shares of the company’s stock, valued at $328,174.08. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Rosty Raykov also recently made the following trade(s):
- On Thursday, August 1st, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.25, for a total value of $15,193.75.
Fennec Pharmaceuticals Stock Performance
Shares of FENC stock opened at $4.62 on Thursday. The stock has a fifty day moving average price of $5.60 and a 200 day moving average price of $7.28. The stock has a market cap of $126.26 million, a PE ratio of 155.67 and a beta of 0.26. Fennec Pharmaceuticals Inc has a 1 year low of $4.58 and a 1 year high of $11.92. The company has a debt-to-equity ratio of 9.86, a quick ratio of 7.75 and a current ratio of 8.02.
Hedge Funds Weigh In On Fennec Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company acquired a new position in shares of Fennec Pharmaceuticals in the second quarter worth $69,000. WINTON GROUP Ltd acquired a new position in shares of Fennec Pharmaceuticals in the second quarter worth $409,000. Acadian Asset Management LLC acquired a new position in shares of Fennec Pharmaceuticals in the second quarter worth $49,000. Rhumbline Advisers raised its holdings in shares of Fennec Pharmaceuticals by 44.7% in the second quarter. Rhumbline Advisers now owns 29,110 shares of the company’s stock worth $178,000 after acquiring an additional 8,987 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Fennec Pharmaceuticals by 42.8% in the second quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company’s stock worth $420,000 after acquiring an additional 20,602 shares during the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts have recently commented on FENC shares. HC Wainwright reduced their price target on Fennec Pharmaceuticals from $15.00 to $13.00 and set a “buy” rating for the company in a report on Thursday, August 22nd. Wedbush reaffirmed an “outperform” rating and set a $14.00 price objective (down from $16.00) on shares of Fennec Pharmaceuticals in a report on Tuesday, August 13th. Finally, Craig Hallum reduced their price objective on Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, August 14th.
Check Out Our Latest Research Report on Fennec Pharmaceuticals
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Articles
- Five stocks we like better than Fennec Pharmaceuticals
- How Investors Can Find the Best Cheap Dividend Stocks
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Roth IRA Calculator: Calculate Your Potential Returns
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Want to Profit on the Downtrend? Downtrends, Explained.
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.